Ketim Technologies

Personalised Blood-Based Biomarkers to Predict Postpartum Depression

  • Stage Product In Development
  • Industry Biotechnology
  • Location Brisbane QLD, Australia
  • Currency AUD
  • Founded March 2024
  • Employees 4
  • Incorporation Type LLC
  • Website ketim.com.au

Company Summary

Ketim Technologies is redefining maternal mental health care with the first blood-based, predictive diagnostic for postpartum depression (PPD). Unlike current screening tools that rely on subjective questionnaires after symptoms appear, Ketim’s patented biomarker panel and AI-powered interpretation software identify risk months before onset with 94% accuracy.

Advisors

  • Scott Fry
    Unconfirmed
    Carrie Hillyard
    Unconfirmed

Previous Investors

  • Scott Fry
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free